Delphic has acquired the diagnostics business of IQur, a biotechnology company specialising in chronic liver disease.
Delphic said the acquisition will enable the company to leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood borne virus screening.
IQur, building upon promising early results, has made the decision to focus on its vaccines programme, developing therapeutic and prophylactic vaccines for hepatitis, other infections and for cancer.
It continues to supply its ELF liver fibrosis test in partnership with Siemens.
